KEGG   DRUG: Rozanolixizumab
Entry
D12182                      Drug                                   
Name
Rozanolixizumab (USAN/INN);
Rozanolixizumab (genetical recombination) (JAN);
rozanolixizumab-noli;
Rystiggo (TN)
Product
Formula
C6462H9984N1704O2016S44
Exact mass
145119.8822
Mol weight
145209.4836
Sequence
(Heavy chain)
EVPLVESGGG LVQPGGSLRL SCAVSGFTFS NYGMVWVRQA PGKGLEWVAY IDSDGDNTYY
RDSVKGRFTI SRDNAKSSLY LQMNSLRAED TAVYYCTTGI VRPFLYWGQG TLVTVSSAST
KGPSVFPLAP CSRSTSESTA ALGCLVKDYF PEPVTVSWNS GALTSGVHTF PAVLQSSGLY
SLSSVVTVPS SSLGTKTYTC NVDHKPSNTK VDKRVESKYG PPCPPCPAPE FLGGPSVFLF
PPKPKDTLMI SRTPEVTCVV VDVSQEDPEV QFNWYVDGVE VHNAKTKPRE EQFNSTYRVV
SVLTVLHQDW LNGKEYKCKV SNKGLPSSIE KTISKAKGQP REPQVYTLPP SQEEMTKNQV
SLTCLVKGFY PSDIAVEWES NGQPENNYKT TPPVLDSDGS FFLYSRLTVD KSRWQEGNVF
SCSVMHEALH NHYTQKSLSL SLGK
(Light chain)
DIQMTQSPSS LSASVGDRVT ITCKSSQSLV GASGKTYLYW LFQKPGKAPK RLIYLVSTLD
SGIPSRFSGS GSGTEFTLTI SSLQPEDFAT YYCLQGTHFP HTFGQGTKLE IKRTVAAPSV
FIFPPSDEQL KSGTASVVCL LNNFYPREAK VQWKVDNALQ SGNSQESVTE QDSKDSTYSL
SSTLTLSKAD YEKHKVYACE VTHQGLSSPV TKSFNRGEC
(Disulfide bridge: H22-H96, H131-L219, H144-H200, H223-H'223, H226-H'226, H258-H318, H364-H422, H'22-H'96, H'131-L-219, H'144-H'200, H'258-H'318, H'364-H'422, L23-L93, L139-L199, L'23-L'93, L'139-L'199)
  Type
Peptide
Remark
Therapeutic category: 6399
ATC code: L04AG16
Product: D12182<JP/US>
Efficacy
Autoimmune disease treatment, Anti-Fc receptor antibody
  Disease
Generalized myasthenia gravis (anti-acetylcholine receptor or anti-muscle specific tyrosine kinase antibody positive) [DS:H01594]
  Type
Monoclonal antibody
Target
FCGRT [HSA:2217] [KO:K24019]
Interaction
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
  L04 IMMUNOSUPPRESSANTS
   L04A IMMUNOSUPPRESSANTS
    L04AG Monoclonal antibodies
     L04AG16 Rozanolixizumab
      D12182  Rozanolixizumab (USAN/INN) <JP/US>
USP drug classification [BR:br08302]
 Antimyasthenic Agents
  Rozanolixizumab
   D12182  Rozanolixizumab (USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
 6  Agents against pathologic organisms and parasites
  63  Biological preparations
   639  Miscellaneous
    6399  Others
     D12182  Rozanolixizumab (USAN/INN); Rozanolixizumab (genetical recombination) (JAN)
Target-based classification of drugs [BR:br08310]
 Not elsewhere classified
  Organismal systems
   Immune system
    FCGRT
     D12182  Rozanolixizumab (USAN/INN) <JP/US>
New drug approvals in the USA [br08319.html]
 New molecular entities and new therapeutic biological products
  D12182
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D12182
New drug approvals in Japan [br08318.html]
 Drugs with new active ingredients
  D12182
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D12182
Pharmacogenomic biomarkers [br08341.html]
 Somatic variations in targeted cancer therapies
  D12182
Other DBs
CAS: 1584645-37-3
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system